TP53 and neoplasm: Through extensive comparison of tumor development from targeting Lfng-expressing centroacinar cells and Mist1-expressing acinar cells with the same set of Kras and p53 mutations, we showed that Lfng-expressing centroacinar cells are resistant to targeting by KrasG12D alone or in combination with p53R172H.